Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
PIQ.AX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.20
N/A
-0.01
vs -0.00
Q4.20
N/A
-0.02
vs -0.01
Q2.21
N/A
-0.01
vs -0.01
Q4.21
N/A
-0.03
vs -0.02
Q2.22
N/A
-0.02
vs -0.01
Q4.22
N/A
-0.03
vs -0.03
Q2.23
N/A
-0.02
vs -0.02
Q4.23
N/A
-0.03
vs -0.03
Q2.24
N/A
-0.02
vs -0.02
Q4.24
N/A
-0.03
vs -0.03
Sales Growth
YoY
Current
Estimates
Q4.20
-35%
597.4K vs 925.1K
Q2.21
+20%
2.1M vs 1.8M
Q4.21
+6%
631.2K vs 597.4K
Q2.22
+30%
2.8M vs 2.1M
Q4.22
+22%
767.1K vs 631.2K
Q2.23
-13%
2.4M vs 2.8M
Q4.23
-29%
541.7K vs 767.1K
Q2.24
+10%
2.7M vs 2.4M
Q4.24
+55%
837.4K vs 541.7K
Q2.25
-69%
812.9K vs 2.7M
Return on Equity
QoQ
Q2.21
-13%
-0.13
vs -0.23
Q4.21
-65%
-0.65
vs -0.13
Q2.22
-53%
-0.53
vs -0.65
Q4.22
-56%
-0.56
vs -0.53
Q2.23
-26%
-0.26
vs -0.56
Q4.23
-70%
-0.70
vs -0.26
Q2.24
-28%
-0.28
vs -0.70
Q4.24
-82%
-0.82
vs -0.28
Institutionnal Ownership
Relative Strength
PIQ.AX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
354%2025-Revenue
-63%2025-EPS
10%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.
ASX
Unprofitable
Unprofitable
0.01Â ( 2.44%)
Pre-market NaN$0.00 (0.00%)
Relative Strenght
Volume Buzz
394%
Earning Acce
No
Dist 52w H.
63%Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How PIQ.AX compares to sector?